ReviewOncology letters2026
New and emerging strategies for targeting cancers: Challenges and opportunities (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite improvements in treatment strategies for cancer patients, the response to treatment by chemotherapy or immunotherapy has benefited a small percentage of cancer patients, depending on tumor histology and other host factors. The mechanism of resistance is poorly understood because cancer cells exhibit extensive plasticity, enabling them to acquire resistance to chemo- and immunotherapy. This review summarizes the current understanding of interactions between chemo- and immunotherapy and their targets, including recent advancements in the regulatory mechanisms that control chemo- and/or immunotherapy response and resistance in cancer. Furthermore, a variety of chemotherapy and/or immunotherapies are discussed, along with recent developments aimed at preventing resistance and relapses following treatment, with a focus on upcoming initiatives to improve the efficacy of chemo- and immunotherapy for cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.